April 2022: Some Medicare Advantage Organization Denials of Prior Authorization Requests Raise Concerns About Beneficiary Access to Medically Necessary Care With there being the potential concern of MAOs having the ability to increase profits by denying payments and access to
Thank you for attending the WRA 14th Annual Conference
Thank you to everyone who attended the 2021 14th Annual Conference in Leavenworth! If you still need to complete the CME evaluation and/or claim credit, please contact Emily Jones at admin@warheumatology.org or 206-956-3621. Please help us thank our generous sponsors
Introducing Our Stories Rx
As an initial convening, Our Stories Rx is hosting a virtual roundtable conversation with Antonio Ciaccia, who served as the government affairs director for the Ohio Pharmacists Association in 2018, when a state audit revealed a PBM-led spread pricing scheme
Online Registration Is Closed
Washington Rheumatology Alliance’s 14th Annual Conference September 17-19, 2021 Sleeping Lady Mountain Resort 7375 Icicle Road Leavenworth, WA 98826 Online registration is now closed. Onsite registration will be available; please contact Sleeping Lady directly regarding room availability. Your registration includes the
Genentech Stance on Most Favored Nations (MFN) Model
On December 15, 2020, Genentech led a discussion about how the Most Favored Nations (MFN) model threatens provider and patient access to existing and future medicines; we share your concerns that this could have a detrimental impact on your practice
Downloadable Resources from the Arthritis Foundation
The Arthritis Foundation has free downloadable brochures and fact sheets through the AF Store that you can save to your office desktop. The brochures and fact sheets can be e-mailed to patients or you can print copies in-office and hand
Biosimilars Could Generate $100 Billion in Savings Over Next Five Years, New Report Finds
WASHINGTON, D.C. — A new report from the IQVIA Institute for Human Data Science has determined that biosimilars are on track to reduce drug costs by $100 billion over the next five years if their use rises. The future of this lower-cost
Coronavirus: What Chronic Illness Patients Need to Know
From CreakyJoints: We’ve been hearing many questions and concerns from our global patient community about the continued spread of coronavirus across the U.S. and around the world. And while people with disabilities and chronic diseases have even more of a
Regence Rituxan to Ruxience has been Reversed
Regence Policy Reversed: The decision from Regence to mandate the switch from Rituxan patients to Ruxience has been reversed and Regence will approve Rituxan patients currently on treatment to continue for 1 year. If you have already submitted the authorization
Interstitial lung disease exacerbates rheumatoid arthritis activity, related conditions
Patients with interstitial lung disease demonstrated a higher proportion of comorbidities and rheumatoid arthritis activity, as well as rheumatoid arthritis-related conditions, according to a presenter at the EULAR 2020 Virtual Congress. “Interstitial lung disease is a common extra-articular manifestation of